scholarly journals Asymptomatic Bladder Metastasis from Breast Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Luigi Cormio ◽  
Francesca Sanguedolce ◽  
Giuseppe Di Fino ◽  
Paolo Massenio ◽  
Giuseppe Liuzzi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bladder Wall ◽  
Progesterone Receptors ◽  
Clinical Situation ◽  
Positive Staining ◽  
First Case ◽  
Computed Tomography Scanning ◽  
Bladder Metastasis ◽  
Metastatic Sites

Introduction.Breast cancer is the most common nondermatologic cancer in women. Common metastatic sites include lymph nodes, lung, liver, and bone. Metastases to the bladder are extremely rare, with all reported cases presenting with urinary symptoms.Case Report.Herein, we report the first case of completely asymptomatic bladder metastasis from breast cancer, occasionally revealed, 98 months after the initial diagnosis of lobular breast carcinoma, by a follow-up computed tomography scanning showing thickening of left bladder wall and grade II left hydronephrosis. A positive staining for estrogen and progesterone receptors was confirmed by immunohistochemistry.Discussion.The reported case confirms that bladder metastases from breast cancer tend to occur late after the diagnosis of the primary tumor and, for the first time, points out they can be asymptomatic.Conclusion.Such data support the need for careful follow-up and early intervention whenever such clinical situation is suspected.

scholarly journals Metastasis of breast cancer to bladder

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Asma Hadhri ◽  
Rim Abidi ◽  
Najet Mahjoub ◽  
Alia Mousli ◽  
Khalil Mahjoubi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lobular Carcinoma ◽  
Bladder Wall ◽  
Hormonal Treatment ◽  
Left Breast ◽  
Case Presentation ◽  
History Of ◽  
Bladder Metastasis ◽  
One Year ◽  
Immunohistochemical Studies

Abstract Background Breast cancer is the leading cause of cancer death in women, and most breast cancer related deaths are due to metastasis. Urinary bladder metastasis from breast cancer is rarely reported in the literature. Case presentation We report a case of a 77-year-old female with history of left breast cancer, who presented a thickening of the bladder wall at pelvic ultrasound. Biopsy confirmed that the origin was lobular carcinoma of breast origin. The patient received chemotherapy, but the clinical course of the patient was very aggressive and she died one year later. Conclusion Bladder metastasis from breast cancer is rare, but the literature reveals an increase in such occurrence over the last few years. Pathologic diagnosis relies on immunohistochemical studies. Chemotherapy and hormonal treatment represent the standard therapy, with radiotherapy being used only to control bladder bleeding. The prognosis is usually poor.

scholarly journals Ovarian ependymoma presenting in pregnancy: a case report and literature review

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Bo Jin ◽  
Jingjing Jiang ◽  
Hongfa Peng
Keyword(s):  
Early Stage ◽  
Progesterone Receptors ◽  
Ovarian Neoplasm ◽  
Ependymal Cells ◽  
Positive Staining ◽  
Case Presentation ◽  
Pathological Type ◽  
Mother And Child ◽  
Rare Malignancy

Abstract Background Ovarian ependymoma is a rare malignancy. Because of the extreme rarity, certain features of the neoplasm, including its clinical behaviour and optimal therapy, are incompletely characterized. Case presentation A 32-year-old pregnant woman at term presented with a left ovarian neoplasm that occurred in the early stage of pregnancy. She underwent left adnexectomy during the caesarean section, and the neoplasm was histologically and immunohistochemically identified to be ovarian ependymoma. Immunohistochemical staining with oestrogen receptors and progesterone receptors showed strong positive staining. According to reports in the literature, the pathological type of ovarian ependymoma in our patient was the extra-axial type. Interestingly, the foetus was also found to have bilateral ependymal cysts during pregnancy. The patient received no further surgical treatment or adjuvant therapy. She and her 14-month-old baby both have no evidence of disease at present. The follow-up of both mother and child is still continuing. Conclusions The case presented here illustrates high levels of oestrogen during pregnancy may stimulate viable malignant ependymal cells to proliferate. Hence, young women with extra-axial-type ependymomas may not be suitable for fertility preservation. Moreover, hormone-based therapies can be a potentially effective treatment for women with extra-axial ependymomas.

scholarly journals A Bladder Wall Angiomyolipoma as a Manifestation of Tuberous Sclerosis: First Case Report

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Mehmet Kalkan ◽  
Coşkun Şahin ◽  
Ömer Etlik ◽  
Ergun Uçmaklı
Keyword(s):  
Tuberous Sclerosis ◽  
Left Kidney ◽  
Bladder Wall ◽  
Hypovolemic Shock ◽  
Renal Angiomyolipoma ◽  
Lower Pole ◽  
Immunohistochemical Examination ◽  
First Case ◽  
Wall Mass

A 21-year-old female patient admitted to the emergency department complaining of left side pain. Hypovolemic shock, which was probably caused by retroperitoneal bleeding from left sided renal angiomyolipoma, was developed. Abdominal computed tomography showed multiple fat containing lesions in different, regions including right bladder wall, lower pole of left kidney, and right kidney. Some lesions compatible with tuberous sclerosis such as angiofibromas, Shagreen patches, myocardial, and brain hamartomas were also detected. Bladder wall mass showing intra- and extravesical extensions was seen at exploration. We removed the tumor completely preserving bladder trigone. Angiomyolipoma located at lower pole of left kidney was also removed. Diagnosis of bladder angiomyolipoma was confirmed by the immunohistochemical examination. Recurrent or residual mass was not detected at the three-months-follow-up. We report the first case of bladder angiomyolipoma confirmed by histopathologically as a tuberous sclerosis.

scholarly journals Metastatic Breast Cancer to the Urinary Bladder in the Caribbean

2021 ◽  
pp. 1586-1590
Author(s):  
Saara Mohammed ◽  
Atiba Akii Bua
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Urinary Bladder ◽  
Lymph Nodes ◽  
Cancer Treatment ◽  
Metastatic Disease ◽  
Bladder Wall ◽  
Metastatic Breast ◽  
The Caribbean ◽  
Metastatic Sites

One of the most common cancers amongst women is breast cancer. The most common metastatic sites are the lymph nodes, lungs, liver, and bone. Metastatic spread to the urinary bladder is rare, and this case, as far as we are aware, is the first reported in the Caribbean. This patient developed urinary symptoms 4 years after her diagnosis of breast cancer. CT imaging showed thickening of the bladder wall, and histology confirmed metastatic breast cancer. As imaging modalities and cancer treatment improve, patients live longer with metastatic disease, and we will potentially see more unusual presentations of metastatic disease.

Longitudinal follow-up of breast cancer patients with the tumor markers CA 549 and CA 15.3

1995 ◽  
Vol 10 (1) ◽  
pp. 30-34 ◽  
Author(s):  
L. Vankrieken ◽  
F. Heureux ◽  
J. Longueville ◽  
R. De Hertogh
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Clinical Situation ◽  
Breast Cancer Patients ◽  
Significant Information ◽  
Ca 15.3 ◽  
Cutoff Levels

In order to verify the efficiency of the tumor markers CA 15.3 and CA 549 in the follow-up of breast cancer patients, it was necessary first to check the cutoff levels of each tumor marker in women with an increased age-related risk, but with no evidence of disease. From 132 serum samples in this age group, we confirmed the CA 549 cutoff level of 12.1 U/ml. However, the cutoff of CA 15.3 was 34 U/ml, which is higher than previously reported in the literature. Fifty-two breast cancer patients with or without metastases at the time of entry into the study were followed for 2 to 3 years with both tumor markers. The sensitivity, specificity and the test efficiency for the presence of metastases were analyzed with each tumor marker. Taking into account the different cutoff levels, we concluded that both tumor markers can be used independently to follow the clinical situation of patients. In several cases an increase in both tumor markers was observed before a clinical diagnosis of metastases could be made. Combination of these two tumor markers gave no more significant information about the patient's clinical situation than each tumor marker alone.

scholarly journals Late urinary bladder metastasis from breast cancer

2019 ◽  
Vol 91 (1) ◽  
pp. 60-62 ◽  
Author(s):  
Aldo Franco De Rose ◽  
Federica Balzarini ◽  
Guglielmo Mantica ◽  
Carlo Toncini ◽  
Carlo Terrone
Keyword(s):  
Breast Cancer ◽  
Urinary Bladder ◽  
Bladder Wall ◽  
Unusual Site ◽  
Left Flank ◽  
History Of ◽  
Bladder Metastasis ◽  
Metastatic Involvement ◽  
Left Flank Pain ◽  
Rule Out

Introduction: Breast cancer (BrC) is the most common non-dermatologic cancer in women. It frequently metastasizes to lung, liver and bone, while the urinary bladder is considered as an unusual site for BrC metastases. Materials and methods: Four years after her first oncologic surgical approach, a known BrC patient complained of a left flank pain, dysuria and urgency. Computed tomography (CT scan) imaging showed an irregular thickening of the left bladder wall and bilateral hydronephrosis. Results: A bladder metastases from BrC was diagnosed based on a histological examination of a transurethral resection of the bladder (TURB-T) specimen. Conclusions: In patients with a history of BrC, urinary bladder screening is not needful. However, if low urinary symptoms persist, an evaluation of the bladder should be considered to rule out metastatic involvement.

Does triple-negative breast cancer (TNBC) have distinct clinicopathologic characteristics and prognostic significance?

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21088-21088
Author(s):  
J. Rhee ◽  
S. Oh ◽  
D. Oh ◽  
S. Im ◽  
S. Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Significance ◽  
Histologic Grade ◽  
University Hospital ◽  
Her2 Status ◽  
Positive Staining ◽  
Clinicopathologic Characteristics ◽  
Node Negative ◽  
Node Positive

21088 Background: Studies have suggested that TNBC, defined by estrogen receptor-negative, progesterone receptor-negative, and HER2-negative, may represent the subset of breast cancer(BC) with different biologic behavior. Here we investigated the clinicopathologic characteristics of TNBC and its prognostic significance in Korean BC patients. Methods: Patients diagnosed as invasive BC and underwent curative surgery at Seoul National University Hospital between Jan. 2000 and Jun. 2003, were reviewed, retrospectively. We excluded the patients whose immunohistochemistry for hormone receptor nor HER2 status had not been evaluated, and who had been treated with adjuvant trastuzumab or neoadjuvant chemotherapy (CT). Clinicopathologic variables (age, T and N stage, endovascular or lymphatic tumor emboli, nuclear and histologic grade, p53, bcl2, Ki67) and 3 year relapse free survival (3YRFS) rate of TNBC were compared with those of non- TNBC. Results: 1,136 patients were eligible for analysis. The median follow-up was 48.7 months. 341 patients underwent breast conserving surgery followed by adjuvant radiotherapy. 249 patients were TNBC and 62.1% of those were node negative. 86.4% of node negative TNBC, 88.3% of node positive TNBC, 53.9% of node negative non-TNBC, and 90.2% of node positive non-TNBC received adjuvant CT. Compared with non-TNBC, TNBC was correlated with younger age (age<35,14.1% vs. 8.2%, p=0.013), higher nuclear and histologic grade(62.2% vs. 23.6%, p=0.001;60.2% vs. 24.6%, p=0.001, respectively); positive staining for p53 (p=0.001) and higher positivity for Ki67 (p=0.001), suggesting the biologic aggressiveness of TNBC. During the follow-up periods, 17.3% of TNBC were relapsed. In particular, 3YRFS in node negative TNBC and non-TNBC were 86% and 96%, respectively (p<0.001). But, in node positive BC, 3YRFS was not different between TNBC and non-TNBC (80.6% vs. 83%, p=0.99). Conclusions: We confirm that TNBC shows more aggressive clinicopathologic characteristics and in particular, higher relapse in node negative BC. Thus, triple-negativity(TN) may be integrated into risk factor analysis in node negative BC. Final results of more detailed molecular analysis for TNBC would be available in the meeting. No significant financial relationships to disclose.

Effect of adjuvant treatment on the circulating CK-19 mRNA-positive tumor cells in patients with early stage breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20012-20012 ◽  
Author(s):  
N. Xenidis ◽  
D. Mavroudis ◽  
S. Apostolaki ◽  
M. Perraki ◽  
A. Stathopoulou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Tumor Cells ◽  
Adjuvant Treatment ◽  
Early Stage ◽  
Progesterone Receptors ◽  
Early Stage Breast Cancer ◽  
Adjuvant Tamoxifen ◽  
Clinical Relapse

20012 Background: To evaluate the effect of adjuvant treatment on the peripheral blood CK-19 mRNA circulating tumor cells (CTCs) in patients with early-stage breast cancer. Methods: CTCs were detected by real-time RT-PCR assay, in 119 patients with estrogen or/and progesterone receptors-positive tumors at the following time points: before the initiation and after the completion of adjuvant chemotherapy and every 3 or 6 months during the period of adjuvant tamoxifen administration. Results: Adjuvant chemotherapy failed to “eliminate” the CTCs in 17 (47%) out of 36 patients with detectable cells in pre-chemotherapy samples; in addition, adjuvant tamoxifen failed to “eliminate” the CTCs in 8 (36.4%) of 22 patients displaying detectable cells in post-chemotherapy samples. The incidence of clinical relapse was significantly (p = 0.017) higher for patients with post-chemotherapy detectable CTCs as well as for patients with persistently detectable CTCs throughout the follow-up period compared with those who did not (65.3% vs 7.3%, respectively; p < 0.001). In multivariate analysis, post-chemotherapy detection of CTCs and their persistence throughout the follow-up period were significantly associated (p = 0.001 and 0.003, respectively) with early relapse. Conclusions: The detection of CK-19 mRNA+ CTCs after adjuvant chemotherapy and during tamoxifen administration is an independent prognostic factor associated with unfavorable outcome. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document